Key result
MitraClip achieves 80% acute procedural success with no major adverse events.
Observational (n=5)
An initial Egyptian experience demonstrates that percutaneous edge-to-edge mitral valve repair with the MitraClip system is feasible and safe for patients with severe mitral regurgitation.
No takes yet. Share an insight, caveat, or question.
Supports feasibility in Egyptian patients; leaves open need for randomized trials before wider adoption.
Khamis et al. (2014) conducted an observational in severe mitral regurgitation (n=5). MitraClip system was evaluated on Acute device success defined as clip implant with reduction of MR to equal or less than grade II. Percutaneous mitral valve repair using the MitraClip system achieved acute procedural success in 80% of patients, with no major adverse events at 30 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: